Trial Profile
Phase I Study to Investigate the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets Given in Single Rising Doses and in Multi Dose Regimens to Subjects With an Allergy to Ragweed Pollen.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ragweed allergy immunotherapy (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors Stallergenes SA
- 26 Oct 2010 New trial record